Target Protein Degradation Market is projected to be over USD 3.6 billion by 2030

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago.
Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.
The USD 3.6 billion (by 2030) financial opportunity within the Target Protein Degradation Market has been analyzed across the following segments:
Type of payment of licensing agreements
• Upfront payments
• Milestone payments
Type of protein degrader
• Degronimids
• Specific BET and DUB inhibitors
• Other protein degraders
Therapeutic area
• Neurodegenerative disorders
• Oncological disorders
• Other therapeutic areas
Route of administration
• Oral
• Intravenous
• Other routes
Key geographical region
• North America
• Europe
• Asia-Pacific
The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:
Get detailed Analysis:

Leave a Reply

Your email address will not be published. Required fields are marked *